Research results from Astrazeneca and British University have been published in LancetResearch shows that this candidate vaccine triggers an immune response to the coronavirus in people over 70, who are at higher risk of more serious diseases. The immune effect needs to be evaluated through the phase 3 trials that have been conducted.
Vaccine candidates against covid-19 Oxford university (The technical name is ChAdOx1 nCoV-19) Show the best level Safety and immune response Effective for healthy adults 18 to 55 years old and people over 56 years old.These data come from a phase 2 clinical trial, which has been published in a scientific journal Lancet And it has been verified during the peer review process.
This British university study has studied the vaccine against 560 healthy people, Of which 240 years old are over 70 years old. Therefore, they found that the drug was better tolerated in the elderly population compared to the elderly and produced similar immune responses in the two groups.
These data are very important because the scientific literature on coronaviruses believes that Older people are at higher risk Died in a more serious way or passed covid-19. Therefore, it is essential that the candidate vaccine is effective and safe for the elderly.
The Phase 2 trial found that the vaccine can cause Few side effects 14 days after the first administration, an immune response is produced in T cells (responsible for detecting and attacking SARS-CoV-2 infected cells); and 28 days after this dose, antibodies (which can be found and attacked in the blood and lymph Viruses circulating in the system).
If the immune response is related to protection against SARS-CoV-2 infection, the new findings may be encouraging.At present, this study has not yet evaluated the efficacy of immunity, which needs to be confirmed by the following tests third step It’s already going on in a larger, more diverse population.
The main author of the study, professor Andrew Pollard The Oxford University commented that elderly people usually have a lower immune response to vaccines, “because the immune system gradually deteriorates with age, which also makes them more susceptible to infection.”
The co-author of the study, Dr. Dr. Maheshi Ramasamy The Oxford University researchers added that the good response of T cells and antibodies is “promising.” He said: “Hopefully this means that our vaccine will help protect one of the most vulnerable people in society, although we need to do more research to ensure this.”
Phase 2 trial
In this candidate vaccine trial, 560 trial participants (160 18 to 55 years old, 160 56 to 69 years old, and 240 over 70 years old) were divided into 10 groups, They received the experimental dose or control vaccine (conjugated meningococcal vaccine). In order to study the elderly in more detail, participants over 55 years of age were also divided into subgroups and received a single dose of the covid vaccine, or 28 days apart.
Participants are at British National Confinement, When people are most likely to be isolated by the disease. Therefore, the trial only included healthy patients, not patients with comorbidities or patients already infected with the coronavirus.
“The Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Initial-Boost Program in Young and Old People (COV002): Single-blind, Randomized, Controlled, Phase 2/3 Trial”. Lancet, November 19, 2020.